Current status and future prospects for disease modification in osteoarthritis

被引:34
作者
Huang, Zhengping [1 ]
Ding, Changhai [1 ,2 ,3 ]
Li, Tianwang [1 ]
Yu, Shirley Pei-Chun [4 ,5 ]
机构
[1] Guangdong Second Prov Gen Hosp, Dept Rheumatol & Immunol, Guangzhou, Guangdong, Peoples R China
[2] Univ Tasmania, Menzies Inst Med Res, Private Bag 23, Hobart, Tas, Australia
[3] Southern Med Univ, Acad Orthoped, Guangdong Prov & Sch Basic Med Sci, Translat Res Ctr, Guangzhou, Guangdong, Peoples R China
[4] Royal North Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia
[5] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW, Australia
关键词
osteoarthritis; disease-modifying osteoarthritis drugs; cartilage; therapeutic targets; non-pharmacological treatments; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; BONE-MARROW LESIONS; SYMPTOMATIC KNEE OSTEOARTHRITIS; SELECTIVE COX-2 INHIBITION; PLACEBO-CONTROLLED TRIAL; MESENCHYMAL STEM-CELLS; CATHEPSIN K INHIBITOR; DOUBLE-BLIND; JOINT DISTRACTION;
D O I
10.1093/rheumatology/kex496
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OA is a chronic, progressive and disabling joint disease, leading to a poor quality of life and an enormous social and economic burden. Current therapies for OA patients remain limited, which creates an area of huge unmet medical need. For some time, researchers have been looking for approaches that can inhibit the structural progression of OA. A variety of potential disease-modifying OA drugs have been developed, targeting cartilage, inflammatory pathways or subchondral bone. In addition, non-pharmacological therapies, including joint distraction and weight loss, draw increasing attention, with some showing disease-modifying potential. Thus we performed a comprehensive review to discuss the current status of disease-modifying therapies in OA and appraise the potentials of emerging novel agents.
引用
收藏
页码:108 / 123
页数:16
相关论文
共 130 条
  • [1] The influence of surgically-induced weight loss on the knee joint
    Abu-Abeid, S
    Wishnitzer, N
    Szold, A
    Liebergall, M
    [J]. OBESITY SURGERY, 2005, 15 (10) : 1437 - 1442
  • [2] ALDEGHERI R, 1994, CLIN ORTHOP RELAT R, P94
  • [3] The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    Alten, Rieke
    Gram, Hermann
    Joosten, Leo A.
    van den Berg, Wim B.
    Sieper, Joachim
    Wassenberg, Siegfrid
    Burmester, Gerd
    van Riel, Piet
    Diaz-Lorente, Maria
    Bruin, Gerardus Jm
    Woodworth, Thasia G.
    Rordorf, Christiane
    Batard, Yannik
    Wright, Andrew M.
    Jung, Thomas
    [J]. ARTHRITIS RESEARCH & THERAPY, 2008, 10 (03)
  • [4] Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage
    Anandacoomarasamy, A.
    Leibman, S.
    Smith, G.
    Caterson, I.
    Giuffre, B.
    Fransen, M.
    Sambrook, P. N.
    March, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (01) : 26 - 32
  • [5] Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis
    Bennell, Kim L.
    Hunter, David J.
    Paterson, Kade L.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (05)
  • [6] Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee - Results of the two-year multinational knee osteoarthritis structural arthritis study
    Bingham, Clifton O., III
    Buckland-Wright, J. Chris
    Garnero, Patrick
    Cohen, Stanley B.
    DougadoS, Maxime
    Adarni, Silvano
    Clauw, Daniel J.
    Spector, Timothy D.
    Pelletier, Jean-Pierre
    Raynauld, Jean-Pierre
    Strand, Vibeke
    Simon, Lee S.
    Meyer, Joan M.
    Cline, Gary A.
    Beary, John F.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (11): : 3494 - 3507
  • [7] Blom AB, 2010, CURR DRUG TARGETS, V11, P620
  • [8] Involvement of the Wnt Signaling Pathway in Experimental and Human Osteoarthritis Prominent Role of Wnt-Induced Signaling Protein 1
    Blom, Arjen B.
    Brockbank, Sarah M.
    van Lent, Peter L.
    van Beuningen, Henk M.
    Geurts, Jeroen
    Takahashi, Nozomi
    van der Kraan, Peter M.
    van de Loo, Fons A.
    Schreurs, B. Wim
    Clements, Kristen
    Newham, Peter
    van den Berg, Wim B.
    [J]. ARTHRITIS AND RHEUMATISM, 2009, 60 (02): : 501 - 512
  • [9] Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling
    Boileau, Christelle
    Tat, Steeve Kwan
    Pelletier, Jean-Pierre
    Cheng, Saranette
    Martel-Pelletier, Johanne
    [J]. ARTHRITIS RESEARCH & THERAPY, 2008, 10 (03)
  • [10] Effects of doxycycline on progression of osteoarthritis - Results of a randomized, placebo-controlled, double-blind trial
    Brandt, KD
    Mazzuca, SA
    Katz, BP
    Lane, KA
    Buckwalter, KA
    Yocum, DE
    Wolfe, F
    Schnitzer, TJ
    Moreland, LW
    Manzi, S
    Bradley, JD
    Sharma, L
    Oddis, CV
    Hugenberg, ST
    Heck, LW
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (07): : 2015 - 2025